uniQure's stock dropped 37.33% after four-year data showed its Huntington's disease gene therapy slowed decline less than at three years, with some data missing and results not statistically significant. Despite the selloff, Wall Street's consensus price target remains high at $68.20, implying 178% upside, as approval of the therapy would be transformative given no current treatments slow Huntington's. The company expects FDA review in late 2026, with a decision about eight months later. Investors face risk from regulatory outcomes but may find opportunity if the therapy gains approval.
UniQure's stock faced a sharp 37.33% drop after new Huntington's disease data, while Wall Street's consensus price target remains at $68.20, implying 178% upside. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 30, 2026 21:42 WIB: out of 100 priced US health stocks, 38 rose and 62 fell. Notable movers include BNGO at USD 1.68 (-2.89%), CI at USD 267.57 (-2.79%), and TMDX at USD 81.93 (-2.55%).
UiPath's stock rose 5% after announcing expanded AI-driven audit solutions with BDO USA and a two-way integration with Snowflake's data platform, enabling real-time, zero-copy data access for automation. Snowflake shares also gained 5%, while Salesfo...
AT&T's Proof of Concept (PoC) Labs celebrate 30 years of helping enterprises test and validate new networking technologies like 5G, edge computing, and private cellular before deployment. The labs have supported over 500 customers annually across ind...
The average price for a three-year-old used car has risen to $32,461, surpassing the cost of new cars from just over a decade ago. This price surge is due to pandemic-related supply disruptions and rising new car prices, making used cars less afforda...
Rosenblatt increased Amazon's price target from $335 to $360, maintaining a Buy rating amid concerns that AI shopping agents might threaten Amazon's retail media business. The firm argues these fears are overstated, noting Amazon's history of adaptin...
The US housing market is experiencing a complex situation where inventory is rising and more sellers are cutting prices, yet home affordability remains difficult due to higher mortgage rates. Realtor.com's report shows a 5.4% increase in active home ...
